http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2009062203-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_04053dda1a4c27102096880d320926a4 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-426 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-2271 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-05 |
| filingDate | 2008-09-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_04107f5d6a8c15bd33692fc668e54e57 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_84342d97c4aba7847d9d857f2810ee82 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1cc823d9a8fefd7c5ff842e9e11eb224 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_590287deca6d836230195ae28fb25251 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_59aed45e091e66eb6bae41fe53ce5690 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d205f98d7ecaf36df2636d11dbd29e97 |
| publicationDate | 2009-03-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2009062203-A1 |
| titleOfInvention | Dipeptidyl peptidase iv inhibitors for the treatment of schizophrenia and depression |
| abstract | A method for therapeutically treating an animal, including a human, for psychosomatic, depressive and neuropsychiatric diseases, such as anxiety, depression, insomnia, schizophrenia, epilepsy, spasm and chronic pain. Administration of a suitable DP IV inhibitor causes the reduction of activity in the enzyme dipeptidyl peptidase (DP IV or CD 26) or of DP IV-like enzyme activity in the brain of mammals and leads as a causal consequence to a reduced degradation of the neuropeptide Y (NPY) and similar substrates by DP IV and DP IV-like enzymes. Such treatment will result in a reduction or delay in the decrease of the concentration of functionally active neuronal NPY (1-36). As a consequence of the resulting enhanced stability of the endogenous NPY (1-36) caused by the inhibition of DP IV activity, NPY activity is prolonged thereby resulting among other things in functionally active NPY Y1 receptor activity thereby facilitating antidepressive, anxiolytic, analgesic, antihypertension and other neurological effects. |
| priorityDate | 2000-10-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 376.